Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB00994
http://purl.obolibrary.org/obo/dinto_DB00994
|
|---|---|
| Preferred Name | neomycin |
| Synonyms |
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
C23H46N6O13
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | neomycin
|
|---|---|
| label | neomycin
|
| DBSynonym |
neomycin b sulfate
usaf cb-19
caswell no. 595
neomycin sulphate
neomycin sulfate
|
| ATCCode |
S03AA01
R02AB01
A07AA01
J01GB05
A01AB08
S01AA03
S02AA07
B05CA09
D09AA01
S01AA07
D06AX04
See more
See less
|
| Definition | A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.
|
| has effect | |
| has pharmacological target | |
| inhibits | |
| type | |
| InChIKey | InChIKey=PGBHMTALBVVCIT-VCIWKGPPSA-N
|
| AHFScode |
84:04.04
52:04.04
|
| Synonym | (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
C23H46N6O13
|
| xref |
RxList:http://www.rxlist.com/cgi/generic3/neomy.htm
National Drug Code Directory:39822-0310-5
PDB:CNY
ChEBI:7507
ChemSpider:8075
PubChem Substance:46505525
Drugs.com:http://www.drugs.com/cdi/neomycin.html
PubChem Compound:8378
PharmGKB:PA450608
Wikipedia:http://en.wikipedia.org/wiki/Neomycin
Drugs Product Database (DPD):527750
See more
See less
|
| CASRN | 1404-04-2
|
| prefixIRI | obo2:dinto_DB00994
|
| SMILES | NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
|
| may interact with |
See more
See less
|
| InChI | InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
|
| DBBrand |
biosol
mycifradin
neomix
neobiotic
tuttomycin
endomixin
myacine
fraquinol
mycifradin-n
myacyne
neolate
fradiomycin
bykomycin
lidamycin creme
nivemycin
vonamycin powder v
neobrettin
neo-fradin
neo-mantle creme
myciguent
neo-rx
fradiomycin sulfate
neofracin
See more
See less
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |